SCEMBLIX was studied vs all standard-of-care* TKIs in patients with newly diagnosed Ph+ CML-CP in ASC4FIRST^2,4,†

*Imatinib, nilotinib, dasatinib, and bosutinib.
 

MMR rates for SCEMBLIX and standard-of-care TKIs^2,5

^‡IS-TKIs included imatinib (400 mg once daily) and other TKIs of nilotinib (300 mg twice daily), dasatinib (100 mg once daily), or bosutinib (400 mg once daily).²

Safety and tolerability profile^2,6,7

AR, adverse reaction; CML, chronic myeloid leukemia; ELTS, EUTOS long-term survival; EUTOS, EUropean Treatment Outcome Study; IS-TKI, Investigator-selected tyrosine kinase inhibitor; MMR, major molecular response; NCCN, National Comprehensive Cancer Network; qd, once daily; TKI, tyrosine kinase inhibitor.

^†ASC4FIRST is a multicenter, randomized, active-controlled, open-label study of 405 adults with newly diagnosed Ph+ CML-CP. Investigators, in consultation with patients, preselected the appropriate TKI and evaluated ELTS risk scores. Patients were then stratified by preselected TKI and ELTS score, then randomized (1:1) to receive either SCEMBLIX or an Investigator-selected TKI (imatinib, nilotinib, bosutinib, or dasatinib). 201 patients received SCEMBLIX at 80 mg qd, and 204 patients received IS-TKIs until unacceptable toxicity or treatment failure occurred. ^2,4